BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//jEvents 2.0 for Joomla//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VTIMEZONE
TZID:America/Chicago
X-LIC-LOCATION:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:19700308T020000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=2SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:19701101T020000
RRULE:FREQ=YEARLY;BYMONTH=11;BYDAY=1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
UID:0b0656148ac2fd0485b98579afb8152929
CATEGORIES:IEC Events (for everyone)
SUMMARY:IEC Symposium at 2018 IID Meeting – Rosen Shingle Creek, Orlando FL
DESCRIPTION:
PHENOTYPE-GENOTYPE CORRELATIONS AND PERSONALIZED MEDICINE IN AT
OPIC DERMATITIS
In addition to this symposium, the IEC is p
roviding the Roadmap for Atopic Dermatitis at IID 201
8. This downloadable PDF helps you make the most of IID 2018 by highlig
hting the symposia, posters, and e-poster sessions that focus on atopic der
matitis!
PROGRAM CHAIRS
- Emma Guttman-Yass
ky, New York, NY, US
- Stephan Weidinger, Kiel, Germany
PROGRAM GOALS- Role of genetic mechanisms in atopic derm
atitis
- Linking genes and immune activation in atopic dermatitis
- The link between the barrier and immune dysregulations in atopic derma
titis
- Relevance of atopic dermatitis phenotypes to ongoing therapeu
tic development
- Future developments of personalized treatment appro
aches for our atopic dermatitis patients.
12:00 – 12:05
pm Welcome and Overview Emma Guttman-Yassky New York, NY
12:05 – 12:30 pm Genetic mechanisms of skin barrier failure
in AD Wilson Liao San Francisco, CA
12:35 – 1:00 pm
Genetic mechanisms in AD Stephan Weidinger Kiel, Germany
1:05
– 1:30 pm Skin barrier, immune dysregulation and itch – therapeut
ic implications Kenji Kabashima Kyoto, Japan
1:35 – 2:00 pm
strong> Differences in immune dysregulation in various AD phenotypes and th
e road to personalized medicine Emma Guttman-Yassky New York, NY
2:00 – 2:15 pm Q and A with plenary speakers
2:1
5– 2:55 pm Abstract Presentations
- # 555 - Integrating s
erum and skin biomarkers to assess disease extent beyond clinical scores, a
dvancing precision therapeutics. Kunal Malik et al., Mount Sinai, New Y
ork, NY
- #559 - ASN002 a dual oral inhibitor of JAK/SYK signali
ng improves clinical outcomes and associated cutaneous inflammation in mode
rate-to-severe atopic dermatitis patients. Emma Guttman et al., Mount S
inai, New York NY
- #1446 - Atopic Cytokines IL4/13 Perturb iPSC
-Derived Itch-Specific Sensory Neurons. Zongyou Guo et al., Columbia Un
iversity, New York, NY
- #1039 - Skin microbiome profiles of ato
pic dermatitis patients segregate into two community composition types that
are stable before and after therapy. John Common et al., A*STAR, Singa
pore
2:55- 3:00 pm Closing Comments Stephan
Weidinger Kiel, Germany
DTSTAMP:20240329T043626
DTSTART;TZID=America/Chicago;VALUE=DATE:20180516
DTEND;TZID=America/Chicago;VALUE=DATE:20180517
SEQUENCE:0
TRANSP:OPAQUE
END:VEVENT
END:VCALENDAR